CD105 Antibody, anti-human, REAlease®
Synonyms: ENG, END, HHT1, ORW1, Endoglin
RECOMBINANT EXTENDED VALIDATION
Clone:
REAL218
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD105 Antibody, anti-human, REAlease®

Flow cytometry applications
FITC
PerCP
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
FITC
Used products:
130-115-182, 130-122-631, 130-115-290
Description:
Human Umbilical Vein Endothelial Cells (HUVEC) were stained with REAlease CD105-FITC (B) or with the corresponding REAL Control (A). REAlease CD105-FITC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD105-FITC (D). Cells were and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

Application imageView details view details

Application imageView details view details

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
FITC
Fixation:
frozen – Acetone
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
FITC
Used products:
130-115-290, 130-115-182
Testing grade:
Description:
Immunofluorescence analysis of a human tonsil cryosection fixed with ice-cold acetone. The section was stained using CD105 Antibody, anti-human, FITC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue).Scale bar: 30 µm.

Application image
Fixation:
frozen – PFA
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:30
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
FITC
Used products:
130-115-290, 130-115-182
Testing grade:
Description:
Immunofluorescence analysis of a human tonsil cryosection fixed with 4% PFA. The section was stained using CD105 Antibody, anti-human, FITC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Extended validation for CD105 Antibody, anti-human, REAlease®
Specificity
Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD105 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD105-PE, clone (REAL218). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD105 Antibody, anti-human, REAlease®
Overview

Clone REAL218 is an antibody fragment derived from the full CD105 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL218 recognizes the CD105 antigen, also known as endoglin, which serves as a receptor for the growth and differentiation factors TGF-β1 and TGF-β3. An epitope of CD105 is recognized by the SH-2 antibody, which was raised against human mesenchymal stromal cells (MSC) that show mesodermal differentiation capacity. Therefore, it can be used for studies on mesengenesis. CD105 is also expressed on mature endothelial cells and on some leukemic cells of B lymphoid and myeloid origin.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

ENG, END, HHT1, ORW1, Endoglin

Detailed product information

Technical specifications

Clone
REAL218
Clonality
monoclonal
Isotype control
Control Antibody
Host
cell line
Type of antibody
Releasable antibodies, Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD105
Distribution of antigen
endothelial cells, B cells, myeloid cells
RRID
AB_2751248, AB_2751254, AB_2819671, AB_2783903, AB_2819672
Resources for CD105 Antibody, anti-human, REAlease®
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD105 Antibody, anti-human, REAlease®
Publications
  1. Bellón, T. et al. (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23 (9): 2340-2345
  2. Barry, F. P. et al. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265: 134-139
  3. Majumdar, M. K. et al. (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J. Cell. Physiol. 185: 98-106

You have previously chosen International as your location.
What do you want to do?